Morphinan compounds
This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ 1 receptor agonist that also has NMDA antagonist activity.
1. A pharmaceutically acceptable salt of a compound represented by the following structural formula:
wherein the pharmaceutically acceptable salt is selected from sulfate, pyrosulfate, bisulfate, sulfite, bisulfate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, sulfonate, xylene sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, 3-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.
2. The pharmaceutically acceptable salt of claim 1 , wherein the salt is selected from chloride, bromide, and phosphate.
3. The pharmaceutically acceptable salt of claim 1 , wherein the salt is phosphate.
4. The pharmaceutically acceptable salt of claim 1 , wherein the deuterium incorporation at each designated deuterium atom is at least 90%.
5. The pharmaceutically acceptable salt of claim 1 , wherein the deuterium incorporation at each designated deuterium atom is at least 95%.
6. The pharmaceutically acceptable salt of claim 1 , wherein the deuterium incorporation at each designated deuterium atom is at least 97%.
7. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7 , further comprising a second therapeutic agent selected from quinidine, quinidine sulfate, oxycodone, and gabapentin.
9. The pharmaceutical composition of claim 7 , wherein the amount of the pharmaceutically acceptable salt of the compound is in the range from 4 mg to 350 mg.
10. The pharmaceutical composition of claim 7 , wherein the amount of the pharmaceutically acceptable salt of the compound is in the range from 10 mg to 90 mg.
11. A method of treating a subject suffering from a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders and neurodegenerative diseases; brain injuries; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; cancer; rheumatoid arthritis; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain, sympathetically mediated pain; pain associated with gastrointestinal dysfunction; mouth pain; back pain; central pain syndrome; complex regional pain syndrome; epileptic seizures; epileptic hemiplegia; acquired epileptiform aphasia (Landau-Kleffner syndrome); severe myoclonic epilepsy of infancy (SMEI); early infantile epileptic encephalopathy; post-stroke seizure; febrile seizures; post-traumatic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer; comprising the step of administering to a subject in need thereof a therapeutically effective amount of the pharmaceutically acceptable salt of claim 1 .
12. The method of claim 11 , wherein the salt is selected from chloride, bromide, and phosphate.
13. The method of claim 11 , wherein the salt is phosphate.
14. The method of claim 11 , wherein the deuterium incorporation at each designated deuterium atom is at least 90%.
15. The method of claim 11 , wherein the deuterium incorporation at each designated deuterium atom is at least 95%.
16. The method of claim 11 , wherein the deuterium incorporation at each designated deuterium atom is at least 97%.
17. The method of claim 11 , wherein the disease or condition is epileptic seizures.
18. The method of claim 17 , wherein the epileptic seizures are generalized epileptic seizures or partial epileptic seizures.
19. The method of claim 11 , wherein the disease or condition is severe myoclonic epilepsy of infancy (SMEI), early infantile epileptic encephalopathy, post-stroke seizures, febrile seizures, or post-traumatic seizures.
20. The method of claim 11 , wherein the amount of the compound administered is in the range from 4 mg to 350 mg.
21. The method of claim 11 , wherein the amount of the compound administered is in the range from 10 mg to 90 mg.
22. The method of claim 11 , further comprising the step of co-administering to the subject a second therapeutic agent selected from quinidine, quinidine sulfate, oxycodone, and gabapentin.